CeQur Simplicity Wearable Insulin Patch Now Available Nationally with Up to 7 Days of Wear and 1-Unit Dosing: Taking on the Mealtime Insulin Problem A new CeQur/Harris Poll finds that half (51%) of U.S. adults managing diabetes with mealtime insulin delivered by pen or syringe/vial miss or skip doses. CeQur®, the company dedicated to simplifying […]
Recent Posts
- November, 2026CeQur Simplicity Wearable Insulin Patch Now Available Nationally with Up to 7 Days of Wear and 1-Unit Dosing
- June, 2026CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™
- CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA
- June, 2025CeQur® Marks 10 Million Mealtime Injections Replaced and Highlights Commercial Expansion
- January, 2025CeQur Closes a $120M Equity Financing to Drive Commercial Growth